By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Drugs and Therapies. According to news reporting originating from Shanghai, People's Republic of China, by NewsRx correspondents, research stated, "Safe and efficient systems capable of specifically targeting brain tumour cells represent a promising approach for the treatment glioblastoma multiforme. Neuropilin-1 (NRP-1) is over-expressed in U87 glioma cells."
Our news editors obtained a quote from the research from Center for Nanotechnology, "In the current study, the tumour specific peptide RGERPPR, which binds specifically to NRP-1, was used as a targeting ligand in a gene delivery strategy for glioblastoma. The RGERPPR peptide was coupled to branched polyethylenimine (PEI, 25 kDa) using heterobifunctional Mal-PEG-NHS, resulting in a novel gene delivery polymer. Polymer/plasmid DNA (pDNA) complexes were formed and their sizes and zeta potentials were measured. Compared with the unmodified mPEG-PEI/pDNA complexes, the RGERPPR-PEG-PEI/pDNA complex led to a significant enhancement in intracellular gene uptake and tumour spheroid penetration. Furthermore, the RGERPPR-PEG-PEI/pDNA complex facilitated enhanced transfection efficiency levels, as well as a reduction in cytotoxicity when tested in U87 glioma cells in vitro. Most significantly of all, when complexes formed with pDsRED-N1 were injected into the tail vein of intracranial U87 tumour-bearing nude mice, the RGERPPR-PEG-PEI complexes led to improved levels of red fluorescence protein expression in the brain tissue."
According to the news editors, the research concluded: "Taken together, the results show that RGERPPR-PEG-PEI could be used as a safe and efficient gene delivery vehicle with potential applications in glioblastoma gene delivery."
For more information on this research see: Targeted gene delivery to glioblastoma using a C-end rule RGERPPR peptide-functionalised polyethylenimine complex. International Journal of Pharmaceutics, 2013;458(1):48-56. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)
The news editors report that additional information may be obtained by contacting J. Wang, Natl Engn Res Center Nanotechnol, Shanghai 200241, People's Republic of China. Additional authors for this research include Y. Lei, C. Xie, W.Y. Lu, Z.Q. Yan, J. Gao, Z.X. Xie, X.Y. Zhang and M. Liu (see also Drugs and Therapies).
Keywords for this news article include: Asia, Shanghai, Drugs and Therapies, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC